Home › Funds › REGENERON PHARMACEUTICALS, INC. › NTLA
REGENERON PHARMACEUTICALS, INC. position in NTLA
Intellia Therapeutics, Inc. · Health Care
REGENERON PHARMACEUTICALS, INC. reported holding 3,702,995 shares of NTLA (Intellia Therapeutics, Inc.) in its Q3 2026 13F filing — a position valued at US$44.7M, representing 24.86% of its reported portfolio and ranking #2 among its reported holdings. REGENERON PHARMACEUTICALS, INC. has disclosed NTLA holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR
How REGENERON PHARMACEUTICALS, INC.'s NTLA position evolved
REGENERON PHARMACEUTICALS, INC. first disclosed a stake in NTLA in Q4 2024 at 3,702,995 shares (US$43.2M). The position peaked in Q3 2025 at 3,702,995 shares, worth US$64.0M. Across 8 filings, REGENERON PHARMACEUTICALS, INC. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 3,702,995 shares valued at US$44.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 3.70M | $43.18M | New |
| Q1 2025 | 3.70M | $26.33M | Hold |
| Q2 2025 | 3.70M | $34.73M | Hold |
| Q3 2025 | 3.70M | $63.95M | Hold |
| Q4 2025 | 3.70M | $33.29M | Hold |
| Q1 2026 | 3.70M | $47.47M | Hold |
| Q2 2026 | 3.70M | $62.65M | Hold |
| Q3 2026 | 3.70M | $44.66M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NTLA and 13F data
NTLA (Intellia Therapeutics, Inc.) is a Health Care company. 38 other funds we track also report a position in NTLA — the largest reported positions include ARK Invest (US$285.5M), RA CAPITAL MANAGEMENT, L.P. (US$76.6M), Amova Asset Management Americas, Inc. (US$49.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NTLA
- ARK Invest 16.88M sh · $285.54M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 4.53M sh · $76.60M · Q2 2026
- Amova Asset Management Americas, Inc. 2.90M sh · $49.03M · Q2 2026
- Contrarius Group Holdings Ltd 1.96M sh · $33.08M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.50M sh · $25.38M · Q2 2026
- Ghisallo Capital Management LLC 1.20M sh · $20.30M · Q2 2026
- IQ EQ FUND MANAGEMENT (IRELAND) Ltd 777.95K sh · $13.16M · Q2 2026
More on REGENERON PHARMACEUTICALS, INC.
FAQ
How long has REGENERON PHARMACEUTICALS, INC. held NTLA?
REGENERON PHARMACEUTICALS, INC. has disclosed NTLA holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is REGENERON PHARMACEUTICALS, INC.'s current position in NTLA?
As of Q3 2026, REGENERON PHARMACEUTICALS, INC. holds 3.70M shares of NTLA (Intellia Therapeutics, Inc.), valued at $44.66M, representing 24.86% of its reported portfolio and ranking #2.
Has REGENERON PHARMACEUTICALS, INC. been buying or selling NTLA?
In the latest 13F filing (Q3 2026), REGENERON PHARMACEUTICALS, INC. held unchanged its position in NTLA. The position peaked in Q3 2025 at 3.70M shares.
Which other funds hold NTLA?
Other major institutional holders of NTLA include ARK Invest, RA CAPITAL MANAGEMENT, L.P., Amova Asset Management Americas, Inc., among 38 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.